Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$31.3 million.

  • Editas Medicine's Free Cash Flow rose 4365.6% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.7 million, marking a year-over-year increase of 556.66%. This contributed to the annual value of -$219.1 million for FY2024, which is 6005.46% down from last year.
  • Latest data reveals that Editas Medicine reported Free Cash Flow of -$31.3 million as of Q3 2025, which was up 4365.6% from -$50.2 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Free Cash Flow peaked at -$23.5 million during Q4 2023, and registered a low of -$60.6 million during Q2 2024.
  • Over the past 5 years, Editas Medicine's median Free Cash Flow value was -$43.1 million (recorded in 2021), while the average stood at -$44.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 4510.8% in 2023, then plummeted by 11787.06% in 2024.
  • Over the past 5 years, Editas Medicine's Free Cash Flow (Quarter) stood at -$37.4 million in 2021, then fell by 14.62% to -$42.9 million in 2022, then surged by 45.11% to -$23.5 million in 2023, then crashed by 117.87% to -$51.3 million in 2024, then skyrocketed by 39.04% to -$31.3 million in 2025.
  • Its Free Cash Flow was -$31.3 million in Q3 2025, compared to -$50.2 million in Q2 2025 and -$47.9 million in Q1 2025.